Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key pancreatic cancer patient populations, covering 171 countries and more than 99% of the global population, delivered in an interactive dashboard-style download.
Use the Extrapolated Worldwide Coverage dashboard to do the following:
View 10-year forecasts of the first-line drug-treatable population and diagnosed incident cases for all 171 countries, stratified by region and World Bank income status.
Aggregate country-level estimates into region-level estimates, according to user preference or as required by regulators for orphan drug designations.
Visualize global correlations between disease risk or size of patient population and key indicators of market opportunity such as GDP per capita and healthcare spend per capita.
Generate and export global heat maps of disease risk or size of patient population.
The Extrapolated Worldwide Coverage dashboard is available as an Excel file in the Downloads section at the top right of this page. It is available for purchase by clients with subscriptions to all 45 countries covered by Clarivate Epidemiology. For subscription and entitlement queries, please contact Clarivate.firstname.lastname@example.org.
Katie Myatt, M.S., Senior Epidemiologist, Epidemiology. Prior to joining Clarivate, Ms. Myatt worked as an epidemiologist for local and state public health departments performing infectious disease surveillance, both endemic and epidemic. Her interests are infectious disease epidemiology and cancer epidemiology. She received both her master’s degree in epidemiology and her bachelor’s degree in biology from the University of Louisville in Kentucky.
Alexandre Vo Dupuy, Pharm.D., M.Sc.
Alexandre Vo Dupuy, M.Sc., Pharm.D., is a principal epidemiologist at Clarivate. Previously, he worked in the fields of consulting and real-world evidence and at a major pharmaceutical company. He obtained his doctor of pharmacy from Descartes University in Paris and his master’s degree in pharmacoepidemiology from the University of Bordeaux. He has worked in multiple therapy areas, with a focus on cancer epidemiology. He also codeveloped a scenario-based forecast for COVID-19.